In brief
On November 1, the Australian government expanded PBS coverage to include child‑friendly granules of Trikafta for cystic fibrosis, Tepezza for thyroid eye disease, and new first‑line Adcetris for Hodgkin lymphoma. Eligible patients can now receive larger quantities of Repatha under a 60‑day prescription initiative. The move is expected to benefit thousands of Australians annually and follows a 511‑listing approval since July 2022.
On November 1, the Australian government announced that the Pharmaceutical Benefits Scheme (PBS) would expand its subsidised listings to accommodate more patients with cystic fibrosis, blood cancer and thyroid eye disease, according to Health Minister Mark Butler. The changes, effective from that date, allow a child‑friendly form of Trikafta, add Tepezza as a treatment for thyroid eye disease, broaden the first‑line use of Adcetris for Hodgkin lymphoma, and modify dispensing limits for Repatha. The initiative is part of the government’s broader effort to increase access to high‑cost medicines, with a total of 511 new and amended listings approved since July 2022.
Trikafta is a combination therapy that targets the underlying genetic defect in cystic fibrosis, a hereditary disease that thickens mucus in the lungs and digestive tract, making breathing and digestion difficult. Traditionally sold as tablets, the new formulation is a granule version suited for children aged six to eleven who weigh less than 30 kg and have trouble swallowing pills. The PBS change is projected to benefit approximately 3,300 Australian children each year; without subsidy, each prescription could cost more than 20,300 Australian dollars (about 14,200 U.S. dollars). This targeted pricing strategy is intended to reduce financial barriers for families managing a costly chronic condition.
In thyroid eye disease, an autoimmune disorder that inflames the tissues around the eyes, the new subsidised drug, Tepezza, offers a non‑steroidal treatment option. Health officials expect the PBS listing to help around 310 Australians annually. Tepezza’s introduction reflects growing evidence that monoclonal antibodies can reverse or halt the progression of eye inflammation, improving patient outcomes and reducing the need for invasive interventions.
The expansion also benefits patients with blood cancer, specifically Hodgkin lymphoma, by adding or extending the availability of Adcetris. Adcetris is an antibody‑drug conjugate that targets CD30, a protein expressed on the surface of malignant cells. The new PBS listing makes Adcetris a first‑line treatment for advanced classical Hodgkin lymphoma, and is estimated to help 370 Australians each year. The move follows clinical trials that have demonstrated superior survival outcomes compared to traditional chemotherapeutic regimens.
For patients managing high cholesterol, the PBS has updated the dispensing limits for Repatha, a medication that lowers low‑density lipoprotein cholesterol. Under the government’s 60‑day prescription initiative, eligible patients may obtain larger quantities of the drug. The capped fees remain modest: 25 Australian dollars per prescription for most patients, reduced to 7.70 Australian dollars for concession card holders. This policy shift is aimed at enabling continuous therapy for individuals who might otherwise face frequent pharmacy visits.
The 60‑day prescription initiative also streamlines pharmacy operations by reducing the administrative load associated with shorter refill cycles. Patients can receive up to two months of medication at a single visit, which lowers the frequency of pharmacy interactions and can improve medication adherence in chronic disease management.
The Australian health department emphasized that the broadened PBS coverage builds on a long‑term strategy to negotiate drug prices while balancing sustainability for the national health system. By expanding child‑specific formulations and first‑line therapies, the government seeks to reduce the economic and clinical burden of rare and complex diseases.
Health Minister Mark Butler acknowledged the importance of early intervention, noting that “the new PBS listings allow more Australians to start effective treatment earlier than ever before.” He highlighted the specific benefit numbers, citing the expected impact on thousands of patients for cystic fibrosis, thyroid eye disease and Hodgkin lymphoma. The government’s press release confirmed that the expanded listings would be rolled out in a phased manner to ensure smooth implementation across the country’s pharmacy network.
The 511 PBS listings since July 2022 represent a significant portion of the country’s investment in targeted therapies. While the listing of Trikafta, Tepezza, Adcetris and Repatha marks only a fraction of those approvals, it signals a commitment to addressing the most pressing unmet needs among chronic disease populations. Stakeholders in the pharmaceutical industry and patient advocacy groups have welcomed the move as a step toward more equitable access to cutting‑edge medicines.
Experts caution that while subsidised access reduces out‑of‑pocket costs, monitoring of long‑term efficacy and safety continues to be essential. The PBS will reportedly maintain its review mechanisms to assess drug performance and ensure that the benefits remain aligned with patient outcomes.